Literature DB >> 10908297

Chick optic lobe contains a developmentally regulated alpha2alpha5beta2 nicotinic receptor subtype.

B Balestra1, S Vailati, M Moretti, W Hanke, F Clementi, C Gotti.   

Abstract

The most widely expressed neuronal nicotinic acetylcholine receptor subtype in chick brain is that containing the alpha4 and beta2 subunits. However, immunoprecipitation and localization studies have shown that some brain areas also contain the alpha2 and/or alpha5 subunits, whose role in the definition of receptor properties is still intriguing. Using subunit-specific polyclonal antibodies, we found that the optic lobe is the chick central nervous system region that expresses the highest level of alpha2-containing receptors. Immunoprecipitation studies of these immunopurified alpha2-containing receptors labeled with the nicotinic agonist [(3)H]epibatidine showed that almost all of them contained the beta2 subunit and that more than 66% contained the alpha5 subunit. Western blot analyses of the purified receptors confirmed the presence of the alpha2, alpha5, and beta2 subunits and the absence of the alpha3, alpha4, alpha6, alpha7, alpha8, beta3, and beta4 subunits. The alpha2-containing receptors are developmentally regulated: their expression increases 25 times from embryonic day 7 to posthatching day 1 in the optic lobe, compared with an increase of only 5-fold in the forebrain. The alpha2-containing optic lobe receptors bind [(3)H]epibatidine (K(d) = 29 pM) and a number of other nicotinic agonists with very high affinity and have a pharmacological profile very similar to that of the alpha4beta2 subtype. They form functional cationic channels when reconstituted in lipid bilayers, with pharmacological and biophysical properties different from those of the alpha4beta2 subtype. These channels are activated by nicotinic agonists in a dose-dependent manner and are blocked by the nicotinic antagonist d-tubocurarine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10908297     DOI: 10.1124/mol.58.2.300

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Formation of functional alpha3beta4alpha5 human neuronal nicotinic receptors in Xenopus oocytes: a reporter mutation approach.

Authors:  P J Groot-Kormelink; J P Boorman; L G Sivilotti
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

2.  Postnatal expression of alpha2 nicotinic acetylcholine receptor subunit mRNA in developing cortex and hippocampus.

Authors:  Jong-Hyun Son; Ursula H Winzer-Serhan
Journal:  J Chem Neuroanat       Date:  2006-10-12       Impact factor: 3.052

3.  An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants.

Authors:  Christopher G Baddick; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2011-05-10       Impact factor: 5.858

Review 4.  Nicotinic agonists, antagonists, and modulators from natural sources.

Authors:  John W Daly
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

Review 5.  Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.

Authors:  Christie D Fowler; Michael A Arends; Paul J Kenny
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

6.  Retrograde inhibition by a specific subset of interpeduncular α5 nicotinic neurons regulates nicotine preference.

Authors:  Jessica L Ables; Andreas Görlich; Beatriz Antolin-Fontes; Cuidong Wang; Sylvia M Lipford; Michael H Riad; Jing Ren; Fei Hu; Minmin Luo; Paul J Kenny; Nathaniel Heintz; Ines Ibañez-Tallon
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-20       Impact factor: 11.205

7.  The novel α7β2-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterization.

Authors:  Milena Moretti; Michele Zoli; Andrew A George; Ronald J Lukas; Francesco Pistillo; Uwe Maskos; Paul Whiteaker; Cecilia Gotti
Journal:  Mol Pharmacol       Date:  2014-07-07       Impact factor: 4.436

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.